Intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar protective immunity to intramuscular inoculation of a full dose of an Al(OH)3-adjuvanted vaccine |
| |
| Institution: | 1. College of Animal Science, Jilin University, Jilin 130062, China;2. State Key Laboratory of Pathogen & Biosecurity, Beijing Institute of Microbiology & Epidemiology, Beijing 100071, China;3. Liaocheng People’s Hospital, Shandong 252000, China;4. Tangshan Maternal and Child Health Care Hospital, Hebei 063000, China;5. Beijing Ditan Hospital, Capital Medical University, Beijing 100071, China;6. Changchun Hygeia Biotech Co, Ltd, Jilin 130000, China;1. Department of Pharmacy, College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Republic of Korea;2. Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Republic of Korea;3. Department of Pharmacy, College of Pharmacy, Chungbuk National University, 52 Naesudong-ro, Heungdeok-gu, Cheongju, Chungcheongbuk-do 28644, Republic of Korea;4. College of Veterinary Medicine, Gyeongsang National University, 501 Jinjudae-ro, Jinju, Gyeongsangnam-do 52828, Republic of Korea;1. Vaccine Research Center, Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China;2. National Center for Protein Science – Shanghai, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201210, China;1. Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan 650118, China;2. Jiangsu Convac Biotechnology Co., Ltd., Taizhou, Jiangsu 225300, China;1. School of Life Sciences, Jilin University, Changchun, PR China;2. National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, PR China;3. Key Laboratory for Molecular Enzymology & Engineering, The Ministry of Education, Jilin University, Changchun, PR China;4. Harbin Center for Disease Control and Prevention, Harbin 150056, PR China;5. State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, PR China;1. Division of Vaccine Research, National Institute of Health, Centers for Disease Control and Prevention, Osong, CheongJu, Chungcheongbuk-do, South Korea;2. Division of Emerging Infectious Disease and Vector Research, National Institute of Health, Centers for Disease Control and Prevention, Osong, CheongJu, Chungcheongbuk-do, South Korea;3. Division of Strategic Planning for Emerging Infectious Disease, Centers for Disease Control and Prevention, Osong, CheongJu, Chungcheongbuk-do, South Korea;4. College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, South Korea;5. Division of Infectious Disease Investigation, Health and Environment Research Institute of Gwangju, 61986, South Korea |
| |
| Abstract: | Enterovirus 71 (EV71) and Coxsackievirus A16 (CVA16) are the two major causative agents of hand, foot and mouth disease (HFMD), which erupts in the Asia-Pacific regions. A bivalent vaccine against both EV71 and CVA16 is highly desirable. In the present study, on the bases that an experimental bivalent vaccine comprising of inactivated EV71 and CVA16 induces a balanced protective immunity against both EV71 and CVA16, we compare the immunogenicity and reactogenicity of one fourth of a full dose of an intradermal vaccine administered by needle-free liquid jet injector with a full dose of an intramuscular vaccine administered by needle-syringe in monkeys. The results suggest that intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar immunogenicity and reactogenicity to intramuscular inoculation of a full dose of an Al(OH)3-adjuvanted vaccine, regardless of whether monovalent or bivalent vaccines were used. Our results support the use of an intradermal bivalent vaccine strategy for HFMD vaccination in order to satisfy the requirements and reduce the costs. |
| |
| Keywords: | Needle-free liquid jet injector Intradermal Intramuscluar |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
